AstraZeneca (AZ) has announced that its immunotherapy Imfinzi (durvalumab) has been approved by the European Commission (EC) ...

Independent Advisor Alliance increased its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 13.0% in the fourth ...

IMFINZITM (durvalumab) has received approval in the European Union as a monotherapy for treating adults with limited-stage ...

AstraZeneca shares have recovered from their brief slump with investors broadly buoyed by the company’s long-term business ...

Results were announced from a trial evaluating durvalumab with FLOT chemo as perioperative treatment for resectable early stage gastric/GEJ cancers.

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

The United Kingdom's stock market has recently faced challenges, with the FTSE 100 index slipping due to weak trade data from China, highlighting concerns over global economic recovery. In this ...

Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers ...

We recently published a list of 10 Best European Stocks to Buy According to Billionaires. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

Barclays analyst Emily Field maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £140.00. The ...

Astra will buy EsoBiotec for up to £770m comprised of an initial £327m payment and another £443m in the future if it hits ...